1. Executive Summary

    1.1. Fact.MR Research Analyzed

    1.2. Global Market – Wheel of Fortune (Opportunity Assessment)

    1.3. Global Market – Mega Trends

2. Market Introduction

    2.1. Global Market Definition

    2.2. Research Scope

3. Associated Indicators Assessment

    3.1. Market Dynamics

        3.1.1. Key Drivers and Trends

        3.1.2. Market Challenges

    3.2. Value Chain

    3.3. Comparison Chart

    3.4. Market – Opportunity Analysis

    3.5. Market Analysis – Investment Feasibility Index

    3.6. Market – PESTLE Analysis

    3.7. Market – Porter’s Five Forces Analysis

    3.8. Market – Market Positioning Assessment by Regions

    3.9. Market Analysis – Forecast Scenario

        3.9.1. Market Analysis – Forecast Factors

    3.10. Price Point Analysis by Region

    3.11. Regulations

    3.12. Voice of Customers

        3.12.1. Decision Purchase Attributes by Region

        3.12.2. Preferred Purchase Points

        3.12.3. Market Opportunity by Region

    3.13. STP Analysis and Go To Market Strategy (Recommendation)

4. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    4.1. Introduction

    4.2. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Type

        4.2.1. Normal-transit Constipation

        4.2.2. Slow-transit Constipation

    4.3. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Therapy

        4.3.1. Pharmacological Therapies

        4.3.2. Non-pharmacological Therapies

    4.4. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Treatment

        4.4.1. Medication

        4.4.2. Surgery

    4.5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Drug

        4.5.1. Serotonin-4 (5-Ht4) Receptor Agonist

        4.5.2. Guanylate Cyclase-C Agonist

        4.5.3. Laxatives

        4.5.4. Stimulants

    4.6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Route of Administration

        4.6.1. Oral

        4.6.2. Injectable

    4.7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by End User

        4.7.1. Hospitals

        4.7.2. Homecare

        4.7.3. Specialty Clinics

    4.8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Region

        4.8.1. North America

        4.8.2. Latin America

        4.8.3. Europe

        4.8.4. Japan

        4.8.5. APEJ

        4.8.6. MEA

5. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    5.1. Introduction

    5.2. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        5.2.1. United States

        5.2.2. Canada

        5.2.3. Market Value Share and BPS Analysis by Country

        5.2.4. Y -o-Y Growth Projections by Country

        5.2.5. Absolute $ Opportunity by Country

        5.2.6. Market Attractiveness Assessment by Country

    5.3. North America Market Value (US$ Mn) and Volume (‘000 Units) by Type

        5.3.1. Market Value Share and BPS Analysis by Type

        5.3.2. Y-o-Y Growth Projections by Type

        5.3.3. Market Attractiveness Assessment by Type

    5.4. North America Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        5.4.1. Market Value Share and BPS Analysis by Therapy

        5.4.2. Y-o-Y Growth Projections by Therapy

        5.4.3. Market Attractiveness Assessment by Therapy

    5.5. North America Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        5.5.1. Market Value Share and BPS Analysis by Treatment

        5.5.2. Y-o-Y Growth Projections by Treatment

        5.5.3. Market Attractiveness Assessment by Treatment

    5.6. North America Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        5.6.1. Market Value Share and BPS Analysis by Drug

        5.6.2. Y-o-Y Growth Projections by Drug

        5.6.3. Market Attractiveness Assessment by Drug

    5.7. North America Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        5.7.1. Market Value Share and BPS Analysis by Route of Administration

        5.7.2. Y-o-Y Growth Projections by Route of Administration

        5.7.3. Market Attractiveness Assessment by Route of Administration

    5.8. North America Market Value (US$ Mn) and Volume (‘000 Units) by End User

        5.8.1. Market Value Share and BPS Analysis by End User

        5.8.2. Y-o-Y Growth Projections by End User

        5.8.3. Market Attractiveness Assessment by End User

6. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    6.1. Introduction

    6.2. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        6.2.1. Brazil

        6.2.2. Mexico

        6.2.3. Argentina

        6.2.4. Chile

        6.2.5. Peru

        6.2.6. Rest of Latin America

        6.2.7. Market Value Share and BPS Analysis by Country

        6.2.8. Y-o-Y Growth Projections by Country

        6.2.9. Absolute $ Opportunity by Country

        6.2.10. Market Attractiveness Assessment by Country

    6.3. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Type

        6.3.1. Market Value Share and BPS Analysis by Type

        6.3.2. Y-o-Y Growth Projections by Type

        6.3.3. Market Attractiveness Assessment by Type

    6.4. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        6.4.1. Market Value Share and BPS Analysis by Therapy

        6.4.2. Y-o-Y Growth Projections by Therapy

        6.4.3. Market Attractiveness Assessment by Therapy

    6.5. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        6.5.1. Market Value Share and BPS Analysis by Treatment

        6.5.2. Y-o-Y Growth Projections by Treatment

        6.5.3. Market Attractiveness Assessment by Treatment

    6.6. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        6.6.1. Market Value Share and BPS Analysis by Drug

        6.6.2. Y-o-Y Growth Projections by Drug

        6.6.3. Market Attractiveness Assessment by Drug

    6.7. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        6.7.1. Market Value Share and BPS Analysis by Route of Administration

        6.7.2. Y-o-Y Growth Projections by Route of Administration

        6.7.3. Market Attractiveness Assessment by Route of Administration

    6.8. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by End User

        6.8.1. Market Value Share and BPS Analysis by End User

        6.8.2. Y-o-Y Growth Projections by End User

        6.8.3. Market Attractiveness Assessment by End User

7. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    7.1. Introduction

    7.2. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        7.2.1. EU-4 (Germany, France, Spain, and Italy)

        7.2.2. United Kingdom

        7.2.3. BENELUX

        7.2.4. NORDIC

        7.2.5. Rest of Europe

        7.2.6. Market Value Share and BPS Analysis by Country

        7.2.7. Y-o-Y Growth Projections by Country

        7.2.8. Absolute $ Opportunity by Country

        7.2.9. Market Attractiveness Assessment by Country

    7.3. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Type

        7.3.1. Market Value Share and BPS Analysis by Type

        7.3.2. Y-o-Y Growth Projections by Type

        7.3.3. Market Attractiveness Assessment by Type

    7.4. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        7.4.1. Market Value Share and BPS Analysis by Therapy

        7.4.2. Y-o-Y Growth Projections by Therapy

        7.4.3. Market Attractiveness Assessment by Therapy

    7.5. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        7.5.1. Market Value Share and BPS Analysis by Treatment

        7.5.2. Y-o-Y Growth Projections by Treatment

        7.5.3. Market Attractiveness Assessment by Treatment

    7.6. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        7.6.1. Market Value Share and BPS Analysis by Drug

        7.6.2. Y-o-Y Growth Projections by Drug

        7.6.3. Market Attractiveness Assessment by Drug

    7.7. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        7.7.1. Market Value Share and BPS Analysis by Route of Administration

        7.7.2. Y-o-Y Growth Projections by Route of Administration

        7.7.3. Market Attractiveness Assessment by Route of Administration

    7.8. Europe Market Value (US$ Mn) and Volume (‘000 Units) by End User

        7.8.1. Market Value Share and BPS Analysis by End User

        7.8.2. Y-o-Y Growth Projections by End User

        7.8.3. Market Attractiveness Assessment by End User

8. CIS & Russia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    8.1. Introduction

    8.2. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Type

        8.2.1. Market Value Share and BPS Analysis by Type

        8.2.2. Y-o-Y Growth Projections by Type

        8.2.3. Market Attractiveness Assessment by Type

    8.3. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        8.3.1. Market Value Share and BPS Analysis by Therapy

        8.3.2. Y-o-Y Growth Projections by Therapy

        8.3.3. Market Attractiveness Assessment by Therapy

    8.4. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        8.4.1. Market Value Share and BPS Analysis by Treatment

        8.4.2. Y-o-Y Growth Projections by Treatment

        8.4.3. Market Attractiveness Assessment by Treatment

    8.5. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        8.5.1. Market Value Share and BPS Analysis by Drug

        8.5.2. Y-o-Y Growth Projections by Drug

        8.5.3. Market Attractiveness Assessment by Drug

    8.6. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        8.6.1. Market Value Share and BPS Analysis by Route of Administration

        8.6.2. Y-o-Y Growth Projections by Route of Administration

        8.6.3. Market Attractiveness Assessment by Route of Administration

    8.7. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by End User

        8.7.1. Market Value Share and BPS Analysis by End User

        8.7.2. Y-o-Y Growth Projections by End User

        8.7.3. Market Attractiveness Assessment by End User

9. Japan Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    9.1. Introduction

    9.2. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Type

        9.2.1. Market Value Share and BPS Analysis by Type

        9.2.2. Y-o-Y Growth Projections by Type

        9.2.3. Market Attractiveness Assessment by Type

    9.3. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        9.3.1. Market Value Share and BPS Analysis by Therapy

        9.3.2. Y-o-Y Growth Projections by Therapy

        9.3.3. Market Attractiveness Assessment by Therapy

    9.4. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        9.4.1. Market Value Share and BPS Analysis by Treatment

        9.4.2. Y-o-Y Growth Projections by Treatment

        9.4.3. Market Attractiveness Assessment by Treatment

    9.5. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        9.5.1. Market Value Share and BPS Analysis by Drug

        9.5.2. Y-o-Y Growth Projections by Drug

        9.5.3. Market Attractiveness Assessment by Drug

    9.6. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        9.6.1. Market Value Share and BPS Analysis by Route of Administration

        9.6.2. Y-o-Y Growth Projections by Route of Administration

        9.6.3. Market Attractiveness Assessment by Route of Administration

    9.7. Japan Market Value (US$ Mn) and Volume (‘000 Units) by End User

        9.7.1. Market Value Share and BPS Analysis by End User

        9.7.2. Y-o-Y Growth Projections by End User

        9.7.3. Market Attractiveness Assessment by End User

10. APEJ Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    10.1. Introduction

    10.2. APEJ Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country

        10.2.1. China

        10.2.2. India

        10.2.3. Australia & New Zealand

        10.2.4. ASEAN

        10.2.5. South Korea

        10.2.6. Rest of APEJ

        10.2.7. Market Value Share and BPS Analysis by Country

        10.2.8. Y-o-Y Growth Projections by Country

        10.2.9. Absolute $ Opportunity by Country

        10.2.10. Market Attractiveness Assessment by Country

    10.3. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Type

        10.3.1. Market Value Share and BPS Analysis by Type

        10.3.2. Y-o-Y Growth Projections by Type

        10.3.3. Market Attractiveness Assessment by Type

    10.4. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        10.4.1. Market Value Share and BPS Analysis by Therapy

        10.4.2. Y-o-Y Growth Projections by Therapy

        10.4.3. Market Attractiveness Assessment by Therapy

    10.5. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        10.5.1. Market Value Share and BPS Analysis by Treatment

        10.5.2. Y-o-Y Growth Projections by Treatment

        10.5.3. Market Attractiveness Assessment by Treatment

    10.6. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        10.6.1. Market Value Share and BPS Analysis by Drug

        10.6.2. Y-o-Y Growth Projections by Drug

        10.6.3. Market Attractiveness Assessment by Drug

    10.7. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        10.7.1. Market Value Share and BPS Analysis by Route of Administration

        10.7.2. Y-o-Y Growth Projections by Route of Administration

        10.7.3. Market Attractiveness Assessment by Route of Administration

    10.8. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by End User

        10.8.1. Market Value Share and BPS Analysis by End User

        10.8.2. Y-o-Y Growth Projections by End User

        10.8.3. Market Attractiveness Assessment by End User

11. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    11.1. Introduction

    11.2. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Country

        11.2.1. GCC Countries

        11.2.2. South Africa

        11.2.3. Turkey

        11.2.4. Israel

        11.2.5. Rest of MEA

        11.2.6. Market Value Share and BPS Analysis by Country

        11.2.7. Y-o-Y Growth Projections by Country

        11.2.8. Absolute $ Opportunity by Country

        11.2.9. Market Attractiveness Assessment by Country

    11.3. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Type

        11.3.1. Market Value Share and BPS Analysis by Type

        11.3.2. Y-o-Y Growth Projections by Type

        11.3.3. Market Attractiveness Assessment by Type

    11.4. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Therapy

        11.4.1. Market Value Share and BPS Analysis by Therapy

        11.4.2. Y-o-Y Growth Projections by Therapy

        11.4.3. Market Attractiveness Assessment by Therapy

    11.5. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Treatment

        11.5.1. Market Value Share and BPS Analysis by Treatment

        11.5.2. Y-o-Y Growth Projections by Treatment

        11.5.3. Market Attractiveness Assessment by Treatment

    11.6. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Drug

        11.6.1. Market Value Share and BPS Analysis by Drug

        11.6.2. Y-o-Y Growth Projections by Drug

        11.6.3. Market Attractiveness Assessment by Drug

    11.7. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration

        11.7.1. Market Value Share and BPS Analysis by Route of Administration

        11.7.2. Y-o-Y Growth Projections by Route of Administration

        11.7.3. Market Attractiveness Assessment by Route of Administration

    11.8. MEA Market Value (US$ Mn) and Volume (‘000 Units) by End User

        11.8.1. Market Value Share and BPS Analysis by End User

        11.8.2. Y-o-Y Growth Projections by End User

        11.8.3. Market Attractiveness Assessment by End User

12. Competitive Assessment

    12.1. Global Market Structure

    12.2. Global Market Competition – a Dashboard View

    12.3. Global Market Company Share Analysis

    12.4. Market Player Competition Footprint Matrix

    12.5. Key Participants Market Presence (Intensity Mapping) by Region

13. Company Profiles

    13.1. Bayer AG

        13.1.1. Overview

        13.1.2. Product Portfolio

        13.1.3. Profitability by Market Segments

        13.1.4. Sales Footprint

    13.2. Allergan

        13.2.1. Overview

        13.2.2. Product Portfolio

        13.2.3. Profitability by Market Segments

        13.2.4. Sales Footprint

    13.3. Bausch Health

        13.3.1. Overview

        13.3.2. Product Portfolio

        13.3.3. Profitability by Market Segments

        13.3.4. Sales Footprint

    13.4. Sanofi

        13.4.1. Overview

        13.4.2. Product Portfolio

        13.4.3. Profitability by Market Segments

        13.4.4. Sales Footprint

    13.5. Takeda Pharmaceutical Company

        13.5.1. Overview

        13.5.2. Product Portfolio

        13.5.3. Profitability by Market Segments

        13.5.4. Sales Footprint

    13.6. Sebela Pharmaceuticals

        13.6.1. Overview

        13.6.2. Product Portfolio

        13.6.3. Profitability by Market Segments

        13.6.4. Sales Footprint

    13.7. Ironwood Pharmaceuticals, Inc.

        13.7.1. Overview

        13.7.2. Product Portfolio

        13.7.3. Profitability by Market Segments

        13.7.4. Sales Footprint

    13.8. Albireo Pharma, Inc.

        13.8.1. Overview

        13.8.2. Product Portfolio

        13.8.3. Profitability by Market Segments

        13.8.4. Sales Footprint

    13.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt)

        13.9.1. Overview

        13.9.2. Product Portfolio

        13.9.3. Profitability by Market Segments

        13.9.4. Sales Footprint

    13.10. Janssen Pharmaceuticals, Inc.

        13.10.1. Overview

        13.10.2. Product Portfolio

        13.10.3. Profitability by Market Segments

        13.10.4. Sales Footprint

    13.11. Synergy Pharmaceuticals Inc.

        13.11.1. Overview

        13.11.2. Product Portfolio

        13.11.3. Profitability by Market Segments

        13.11.4. Sales Footprint

    13.12. Shandong Luoxin Pharmaceutical Group Stock Co., Ltd

        13.12.1. Overview

        13.12.2. Product Portfolio

        13.12.3. Profitability by Market Segments

        13.12.4. Sales Footprint

    13.13. Zydus Cadila

        13.13.1. Overview

        13.13.2. Product Portfolio

        13.13.3. Profitability by Market Segments

        13.13.4. Sales Footprint

    13.14. Boehringer Ingelheim International GmbH

        13.14.1. Overview

        13.14.2. Product Portfolio

        13.14.3. Profitability by Market Segments

        13.14.4. Sales Footprint

    13.15. Abbott Laboratories

        13.15.1. Overview

        13.15.2. Product Portfolio

        13.15.3. Profitability by Market Segments

        13.15.4. Sales Footprint

    13.16. GlaxoSmithKline Plc

        13.16.1. Overview

        13.16.2. Product Portfolio

        13.16.3. Profitability by Market Segments

        13.16.4. Sales Footprint

    13.17. Troikaa Pharmaceuticals Ltd

        13.17.1. Overview

        13.17.2. Product Portfolio

        13.17.3. Profitability by Market Segments

        13.17.4. Sales Footprint

    13.18. Lupin

        13.18.1. Overview

        13.18.2. Product Portfolio

        13.18.3. Profitability by Market Segments

        13.18.4. Sales Footprint

    13.19. East West Pharma

        13.19.1. Overview

        13.19.2. Product Portfolio

        13.19.3. Profitability by Market Segments

        13.19.4. Sales Footprint

    13.20. Ferring B.V.

        13.20.1. Overview

        13.20.2. Product Portfolio

        13.20.3. Profitability by Market Segments

        13.20.4. Sales Footprint

    13.21. Albireo Pharma, Inc.

        13.21.1. Overview

        13.21.2. Product Portfolio

        13.21.3. Profitability by Market Segments

        13.21.4. Sales Footprint

14. Assumptions and Acronyms Used

15. Research Methodology